[Alzheimer's disease - system prepardeness in the context of new developments].

Abstract

Introduction: The possible authorisation of new monoclonal antibody therapies for Alzheimer's disease poses challenges for healthcare systems worldwide. In this paper, the Swiss Memory Clinics association (SMC) analyses the available resources and identifies potential health care shortages. Overcoming potential bottlenecks is a challenge that requires action at various levels. However, our analysis also shows that we are well positioned in Switzerland to integrate new developments into existing care structures.